Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajesh Krishna

Showing results (11-20 of 97) with videos related to

Pageof 10
Sort By:
Clinical Pharmacology and Therapeutics|November 7, 2017
The Emerging Role of Digital Technologies in Early Clinical DevelopmentRajesh Krishna
Journal of Clinical Pharmacology|March 19, 2026
Invisible No More: How Redefining Rare Diseases Can Advance Health EquityRajesh Krishna
Therapeutic Innovation & Regulatory Science|September 18, 2018
Managing Team Innovation in the Research and Development (R&D) Organization: Critical Determinants of Team EffectivenessRajesh Krishna, Hongwei He
Journal of Clinical Pharmacology|December 21, 2007
Commentary on the clinical relevance of concentration/QTc relationships for new drug candidatesDaniel Bloomfield, Rajesh Krishna
Clinical Pharmacology and Therapeutics|November 21, 2018
Clinical Endpoint Bioequivalence Studies Are Needed: A Perspective From Brand DrugsRajesh Krishna, Filippos Kesisoglou
Biomarkers in Medicine|December 8, 2010
Applications of 'decisionable' biomarkers in cardiovascular drug developmentRajesh Krishna, John A Wagner
American Journal of Hematology|April 28, 2011
Neutropenia and anemia with reduced serum vitamin B12Rajesh Krishna, Emma O'Donovan, Barbara J Bain
The AAPS Journal|January 16, 2009
The use of clinical utility assessments in early clinical developmentAnis A Khan, Itay Perlstein, Rajesh Krishna
The AAPS Journal|August 8, 2008
Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetesRajesh Krishna, Gary Herman, John A Wagner
Biopharmaceutics & Drug Disposition|September 6, 2002
Pharmacokinetics and dose proportionality of BMS-204352 after intraarterial administration to ratsRajesh Krishna, Vinod R Shah, Nuggehally Srinivas
Pageof 10

Showing results (11-20 of 97) with videos related to

Sort By:
Pageof 10
Clinical Pharmacology and Therapeutics|November 7, 2017
The Emerging Role of Digital Technologies in Early Clinical DevelopmentRajesh Krishna
Journal of Clinical Pharmacology|March 19, 2026
Invisible No More: How Redefining Rare Diseases Can Advance Health EquityRajesh Krishna
Therapeutic Innovation & Regulatory Science|September 18, 2018
Managing Team Innovation in the Research and Development (R&D) Organization: Critical Determinants of Team EffectivenessRajesh Krishna, Hongwei He
Journal of Clinical Pharmacology|December 21, 2007
Commentary on the clinical relevance of concentration/QTc relationships for new drug candidatesDaniel Bloomfield, Rajesh Krishna
Clinical Pharmacology and Therapeutics|November 21, 2018
Clinical Endpoint Bioequivalence Studies Are Needed: A Perspective From Brand DrugsRajesh Krishna, Filippos Kesisoglou
Biomarkers in Medicine|December 8, 2010
Applications of 'decisionable' biomarkers in cardiovascular drug developmentRajesh Krishna, John A Wagner
American Journal of Hematology|April 28, 2011
Neutropenia and anemia with reduced serum vitamin B12Rajesh Krishna, Emma O'Donovan, Barbara J Bain
The AAPS Journal|January 16, 2009
The use of clinical utility assessments in early clinical developmentAnis A Khan, Itay Perlstein, Rajesh Krishna
The AAPS Journal|August 8, 2008
Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetesRajesh Krishna, Gary Herman, John A Wagner
Biopharmaceutics & Drug Disposition|September 6, 2002
Pharmacokinetics and dose proportionality of BMS-204352 after intraarterial administration to ratsRajesh Krishna, Vinod R Shah, Nuggehally Srinivas
Pageof 10